Beschreibung
Fluconazole inhibits CYP2C8-mediated metabolism of montelukast, modestly increasing montelukast plasma concentrations; the clinical impact is generally minor given montelukast's wide therapeutic index.
Mechanismus
Montelukast is primarily metabolised by CYP2C8 and to a lesser extent CYP3A4; fluconazole inhibits both enzymes, reducing montelukast clearance and elevating systemic exposure.
Klinische Bedeutung
Pharmacokinetic modelling predicts a moderate increase in montelukast AUC; no clinical case reports of montelukast toxicity due to fluconazole have been identified.
Maßnahmen
No dose adjustment is required; standard monitoring is adequate.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.